Non-alcoholic Steatohepatitis Biomarkers Market
Report ID: SQMIG35A2593
Report ID: SQMIG35A2593
sales@skyquestt.com
USA +1 351-333-4748
Report ID:
SQMIG35A2593 |
Region:
Global |
Published Date: December, 2025
Pages:
157
|Tables:
34
|Figures:
74
Global Non-alcoholic Steatohepatitis Biomarkers Market size was valued at USD 1.3 Billion in 2024 and is poised to grow from USD 1.67 Billion in 2025 to USD 12.59 Billion by 2033, growing at a CAGR of 28.7% during the forecast period (2026–2033).
The Global Non-alcoholic Steatohepatitis (NASH) Biomarkers market is experiencing significant growth and is driven by several factors. The market is witnessing increasing prevalence of NASH, which is a chronic liver disease associated with obesity and metabolic disorders.
As the incidence of NASH continues to rise, the demand for accurate and reliable biomarkers for early diagnosis, disease progression monitoring, and therapeutic response evaluation is increasing.
Biomarkers play a crucial role in identifying individuals at risk of developing NASH, differentiating NASH from other liver diseases, and assessing the severity and progression of the disease. Additionally, the market is benefiting from ongoing advancements in biomarker research and development, including the discovery of novel biomarkers and the development of non-invasive diagnostic tools.
Overall, the Global NASH Biomarkers market is poised for growth as it addresses the unmet need for effective diagnostic and monitoring tools for NASH, offering opportunities for market players to introduce innovative biomarker-based solutions.
Market snapshot - 2026-2033
Global Market Size
USD 1.01 billion
Largest Segment
liver fibrosis biomarkers
Fastest Growth
liver fibrosis biomarkers
Growth Rate
28.7% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global Non-alcoholic Steatohepatitis biomarkers Market is segmented by Type, End User and region. Based on Type, the market is segmented into Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers and Others. Based on End User, the market is segmented into Research Institutes and Academics, Diagnostic Centres, Pharmaceutical Companies and CROs, Hospitals and Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
The dominant sub-segment in the type segment of the NASH Biomarkers market is the liver fibrosis biomarkers. Liver fibrosis is a common consequence of NASH and is an important indicator of disease progression. Biomarkers such as enhanced liver fibrosis (ELF) score, FibroTest, and FibroScan are commonly used to assess the degree of liver fibrosis and determine the stage of the disease. These biomarkers help clinicians in evaluating the severity of NASH and making treatment decisions.
The fastest growing sub-segment in the type of the NASH Biomarkers market is the genetic biomarkers. Genetic biomarkers involve the analysis of specific genes or genetic variations associated with NASH. As our understanding of the genetic basis of NASH improves, genetic biomarkers are gaining importance in diagnosing and predicting the risk of developing NASH. Genetic tests, such as genetic profiling and single nucleotide polymorphism (SNP) analysis, are increasingly being used to identify individuals at high risk for NASH and tailor personalized treatment strategies.
To get detailed segments analysis, Request a Free Sample Report
One dominant region in the global non-alcoholic steatohepatitis (NASH) biomarkers market is North America. North America has a well-established healthcare infrastructure, advanced diagnostic technologies, and a high prevalence of NASH, making it a key region for NASH biomarker research and development. The region is home to several major pharmaceutical and biotechnology companies that are actively involved in developing and commercializing NASH biomarkers. Additionally, North America has a strong regulatory framework and reimbursement policies that support the adoption of biomarker-based diagnostics in clinical practice.
One of the fastest growing regions in the global NASH biomarkers market is the Asia-Pacific region. The Asia-Pacific region is witnessing a rising prevalence of NASH due to the increasing prevalence of obesity, sedentary lifestyle, and changing dietary habits. Moreover, there is a growing awareness among healthcare professionals and patients regarding the early detection and management of NASH. As a result, there is an increasing demand for biomarker-based diagnostics in this region. Additionally, countries like China and India are investing in healthcare infrastructure development and research initiatives, which further fuels the growth of the NASH biomarkers market in the Asia-Pacific region.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Prevalence Of Nash Worldwide
Lack Of Standardized Biomarkers And Regulatory Challenges
Request Free Customization of this report to help us to meet your business objectives.
The global market is characterized by a mix of established companies and emerging players. Market participants are focusing on research and development activities to enhance the efficiency and performance of Non-alcoholic Steatohepatitis Biomarkerss. Additionally, strategic collaborations, partnerships, and mergers and acquisitions are prevalent strategies adopted by companies to expand their market presence. The competitive environment is further influenced by factors such as technological advancements, government regulations, and the ability to provide cost-effective and sustainable solutions.
SkyQuest's ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
The global non-alcoholic steatohepatitis (NASH) biomarkers market is witnessing significant growth due to the increasing prevalence of non-alcoholic fatty liver disease (NAFLD) and NASH worldwide. NASH biomarkers play a crucial role in diagnosing and monitoring the progression of the disease, as well as evaluating the efficacy of therapeutic interventions. These biomarkers help in assessing liver fibrosis, inflammation, and oxidative stress, providing valuable insights for patient management and treatment decisions. The market is driven by the growing demand for non-invasive diagnostic tools, advancements in biomarker discovery technologies, and the rising awareness about NASH and its associated complications. As the healthcare industry focuses on personalized medicine and targeted therapies, the development and commercialization of reliable and accurate NASH biomarkers hold great promise in improving patient outcomes and optimizing healthcare resources.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 1.3 Billion |
| Market size value in 2033 | USD 12.59 Billion |
| Growth Rate | 28.7% |
| Base year | 2024 |
| Forecast period | 2026-2033 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Non-alcoholic Steatohepatitis Biomarkers Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Non-alcoholic Steatohepatitis Biomarkers Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Non-alcoholic Steatohepatitis Biomarkers Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Non-alcoholic Steatohepatitis Biomarkers Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
